Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact

Conversations with Giants in Medicine

JCI’s Conversations with Giants in Medicine: Griffin Rodgers

Beginning in the mid-1980s, Dr. Griffin Rodgers, Director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health, led studies demonstrating the effectiveness of the drug hydroxyurea, the first FDA-approved drug for sickle cell disease. Since then, Rodgers has worked on transplant strategies and therapies for sickle cell disease and other hemoglobinopathies while also taking on massive leadership and administrative roles at the NIH, culminating in his appointment to the directorship of the NIDDK in 2007. Watch to hear about how Malcolm Gladwell and Howard Hughes played a role in sickle cell anemia and why it’s fitting to study hematology at a diabetes- and kidney-focused institute.


JCI's Conversations with Giants in Medicine: C. Ronald Kahn

C. Ronald (Ron) Kahn of the Joslin Diabetes Center at Harvard Medical School is a physician-scientist who illuminated much of what we appreciate about the insulin receptor and the means by which it signals. He previously served as president of the American Society for Clinical Investigation and is the scientist with the most publications in the JCI. See the full interview on the JCI website https://www.jci.org/videos/cgms to hear more about Dr. Kahn’s political aspirations beyond the presidency of ASCI and to hear who told him he’d never be a big deal in endocrinology.


JCI's Conversations with Giants in Medicine: Jesse Roth

We take it for granted today that each hormone and other intercellular messenger have their own specific receptors. But this was not the case until the groundbreaking work of Jesse Roth and his colleagues. Roth is best known for his research on cell surface membrane receptors. His studies on the receptors for insulin, growth hormone, and adrenocorticotropic hormone (ACTH) in the early 1970s became the model for many others.


Conversations with Giants in Medicine: Barbara Kahn

Barbara Kahn is the quintessential physician-scientist. Dr. Kahn, of the Beth Israel Deaconess Medical Center and Harvard Medical School, is best known for elucidating molecular mechanisms of type 2 diabetes, obesity, and insulin resistance, with a particular emphasis on the role of the adipocyte in regulating glucose metabolism. In this interview by JCI Editor at Large Ushma Neill, Dr. Kahn discusses her work and history, including tales of going to Studio 54 with Andy Warhol.


JCI's Conversations with Giants in Medicine: Marc Feldmann, Jacques Miller, and Max Cooper

Sir Marc Feldmann, Lasker awardee in 2003 for his role in discovering anti-TNF therapy, acts as interviewer, speaking with the two recipients of the 2019 Albert Lasker Basic Medical Research Award, Max D. Cooper of Emory University and Jacques Miller of the Walter and Eliza Hall Institute of Medical Research. Drs. Miller and Cooper identified and defined the function of T and B cells, uncovering the organizing principle of the adaptive immune system.

 

  • ← Previous
  • 1
  • 2
  • 3
  • 4
  • …
  • 14
  • 15
  • Next →
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts